The US FDA has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for CMT2S.
Few diseases turn the body’s defenses against it as relentlessly as lupus. In people with the condition, immune cells mistake ...